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Abstract  
Aims/hypothesis: Immunohistochemical staining reveals that the enteroviral capsid protein, 
VP1, is present at higher frequency in the insulin-containing islets of patients with recent 
onset type 1 diabetes than in controls. This is consistent with epidemiological evidence 
suggesting that enteroviral infection may contribute to the autoimmune response in type 1 
diabetes. However, immunostaining of VP1 is not definitive since the antibody widely used 
to detect the protein (Dako 5D8/1) might also cross-react with additional proteins under some 
conditions. Therefore, we sought to verify that VP1 immunopositivity correlates with 
additional makers of viral infection.  
Methods: Antigen immunoreactivity was examined in formalin-fixed, paraffin-embedded, 
pancreases from two different collections of type 1 diabetes and control cases; a historical 
collection from the UK and the nPOD cohort (USA).  
Results: VP1 immunoreactivity was present in ~20% of insulin-containing islets of both 
cohorts under stringent conditions but was absent from insulin-deficient islets. VP1 
expression was restricted to beta cells but only a minority of these expressed the antigen. The 
innate viral sensor, protein kinase R (PKR) was up-regulated selectively in beta cells that 
were immunopositive for VP1. The anti-apoptotic protein, Mcl-1, was abundant in beta cells 
that were immunonegative for VP1 but Mcl-1 was depleted in cells expressing VP1. 
Conclusions/interpretation: The presence of immunoreactive VP1 within beta-cells in type 
1 diabetes is associated with a cellular phenotype consistent with the activation of antiviral 
response pathways and enhanced sensitivity to apoptosis. However, definitive studies 




Considerable circumstantial evidence has accumulated to suggest that enteroviral infection of 
pancreatic islet beta cells may contribute to the development of autoimmunity in some 
patients with type 1 diabetes [1-4]. This is important since, if verified in a majority of cases, it 
may provide a means to minimise the future development of type 1 diabetes in susceptible 
individuals via a targeted vaccination program.  
The evidence implicating enteroviral infection of pancreatic beta cells has arisen from a 
variety of sources including the successful culture of live enteroviral strains from within the 
pancreases of individuals with type 1 diabetes and the capture of electron microscopic images 
showing the generation of viral arrays within the beta cells of patients [5, 6]. Additionally, the 
common enteroviral capsid protein, VP1, has been detected immunologically in the islet cells 
of patients with recent onset type 1 diabetes, at much higher frequency than in age-matched 
controls [5, 7]. Arguably, this latter evidence is the more persuasive for several reasons. In 
particular, it has been noted that the enteroviral strains isolated during pancreas culture are of 
uncertain provenance [8] and the electron microscopic evidence of viral particle assembly is 
derived from only a very small number of cases [5]. By contrast, enteroviral VP1 was 
detected at high frequency in the islets of more than 60% of patients with recent onset type 1 
diabetes in a large UK cohort [7]. Importantly, however, it must also be recognised that the 
immunolabelling of enteroviral VP1 in islet cells remains equivocal since the specificity of 
the principal antibody employed in these studies (Dako 5D8/1) has been questioned (although 
its ability to detect enteroviral VP1 is not in debate) [9]. Furthermore, the presence of viral 
antigen is detected much more readily than viral RNA in islet cells under most conditions. 
Therefore, it is important that additional evidence is gained to evaluate further the hypothesis 
that the immunodetection of enteroviral VP1 in the islet beta cells of patients with recent 
onset type 1 diabetes is associated with an underlying viral infection.  
In the present study we have addressed this issue in two ways. Firstly, we have made use of a 
second (much more modern) collection of pancreas samples from within the JDRF nPOD 
(Network of Pancreatic Organ donors with Diabetes) program [10] and have compared the 
staining patterns obtained using the 5D8/1 anti-VP1 serum in these samples with that 
obtained previously in the historical UK cohort. This is important since the UK samples were 
collected between 30-50 years ago and were harvested at autopsy in random locations across 
the UK, where entirely different methods of recovery and fixation were employed [11]. By 
contrast, the nPOD program was established much more recently (the collection began in 
2007) in a geographically distinct region (the USA) and uses standard operating procedures 
to ensure consistency of recovery and processing of the samples [10]. Secondly, we have 
evaluated whether, in both cohorts, the detection of VP1 at the level of individual islet cells 
under stringent conditions, is directly correlated with additional markers consistent with the 
establishment of an anti-viral response. In particular, we have monitored the expression of 
two further proteins, protein kinase R (PKR) and myeloid cell leukemia sequence-1 (Mcl-1) 
in concert with VP1. PKR is an enzyme responsible for the activation of antiviral cascades 
within cells and is known to be induced during enteroviral infection of cells [12, 13]. Mcl-1 is 
an anti-apoptotic protein which is subject to rapid turnover in cells such that it is degraded 
quickly during the translational arrest that ensues following viral infection [14]. Accordingly, 
we present a detailed analysis of the correlations between the immunodetection of VP1, 






Subjects. Pancreases recovered from 6 patients with recent onset type 1 diabetes mellitus 
(disease duration ≤ 18 months) and one with type 1 diabetes for 12 years were selected from 
within a UK cohort used previously [7]. The specimens were studied with ethical approval 
and had been variously fixed in buffered p-formaldehyde, un-buffered formol saline or 
Bouin’s fixative. They were all paraffin-embedded. 5 of the 7 pancreases were removed at 
autopsy and two were recovered at the time of organ donation (D4 and D5).  The patients 
were typically between 1-18 years old but one was 42y, raising the overall mean to 19.0±5.0y 
(ESM Table 1). A second cohort of 17 type 1 diabetes mellitus pancreases (mean age: 
25.7±2.9y) and 12 age-matched non-diabetic controls (mean age: 27.9±7.1 years) was 
obtained through the JDRF Network for Pancreatic Organ Donors with Diabetes (nPOD) 
program (Table 1 and ESM Table 2) [10].  
 
Immunohistochemistry. Sections (4μm; mounted on glass slides coated in (3-
Aminopropyl)-triethoxysilane; Sigma, UK) were processed and labelled using a standard 
immunoperoxidase technique [7, 15, 16]. With the exception of insulin, all antigens were 
unmasked by heating in 1mM EDTA (Sigma, UK) buffer pH8.0, in a pressure cooker in a 
microwave oven on full power (800W) for 20 min, followed by 20 min of cooling at room 
temperature. Primary antibodies were applied as detailed in ESM Table 3 and Dako REAL™ 
Envision™ Detection System (Dako, UK) used for antigen detection. Some slides were 
processed in the absence of primary antibody or with isotype control antisera to confirm the 
specificity of labelling. Slides were analysed by light microscopy. 
 
Combined immunofluorescence. For co-localisation studies, anti-insulin and anti-VP1 
immunoreactivity were detected using an AlexaFluor
®
 488-conjugated anti-guinea pig 
antibody and an AlexaFluor
®
 568 conjugated anti-mouse antibody respectively (Invitrogen, 
Paisley, UK). To determine if the enteroviral VP1 protein co-localised with either PKR or 
Mcl-1 in beta cells, primary antibodies were incubated as described in Online Supplementary 
Table 2. The primary antibodies were detected with relevant goat secondary antibodies 
conjugated to AlexaFluor
®
 488 or 568 (Invitrogen) or with goat anti-guinea-pig DyLight 405 
(Stratech, UK). Control sections were stained with relevant primary and secondary antisera to 
confirm that no cross-reactivity was detected.  Sections were mounted in Vectashield hard-set 
mounting medium (Vector Laboratories, Peterborough, UK) under glass cover slips.  Images 
were captured using a Nikon Eclipse 80i microscope (Nikon, Surrey, UK) and overlaid using 
NIS-Elements BR 3.0 software (Nikon) to study the relative localisation of each antigen. 
Sections directly adjacent to those stained with the combined method were stained with an 
anti-glucagon antibody (rabbit; Dako) or an anti-insulin (guinea-pig; Dako) using a standard 
immunoperoxidase technique in order to determine total islet numbers in the sections and to 
distinguish insulin containing islets (ICIs) from insulin deficient islets (IDIs).  
 
RESULTS 
Enteroviral VP1 is frequently detected in islets of type 1 diabetes patients from both the 
UK and nPOD cohorts. Previous analysis of the UK cohort had revealed the expression of 
the enteroviral VP1 protein in the insulin-containing islets (ICIs) of 44 of 72 (61%) recent-
onset type 1 diabetes patients. This compared with only 3 of 50 paediatric and neonatal 
controls (Figure 1) [7]. The recent-onset type 1 diabetes pancreas samples collected within 
the UK cohort are unique in that they represent about half of all such cases described 
worldwide and because they come from individuals with short duration of disease. However, 
they were harvested between 30-50 years ago and were fixed using non-standardised 
protocols [11]. We considered it important, therefore, to establish whether enteroviral VP1 
staining is also present in a different cohort, collected more recently, from a geographically 
different population, using more standardised protocols. The JDRF nPOD collection  
provided this opportunity [10]. A comparison of the samples available within these two 
cohorts is shown in Table 2 and it is noteworthy that the donor with the shortest duration of 
disease among the nPOD samples had been diabetic for 1 year. Moreover, the mean disease 
duration among this group was approximately 12 years. This compares with an average 
disease duration of less than 1 year in the UK cohort (Table 2).  
Initial experiments using an enteroviral VP1 antibody (5D8/1) were performed to determine 
the optimal concentration for routine use which allowed clear immunodetection of VP1 with 
minimal background staining. 17 type 1 diabetes nPOD cases and 12 non-diabetic controls 
were then immunostained (Table 1 and ESM Table 2). Among the nPOD controls, only 1 
case was found in which a combined total of more than 5 individual islet cells were 
immunopositive for VP1 in the entire pancreas section. Accordingly, this value was chosen to 
represent the threshold limit to define immunopositivity for VP1 in control samples. By 
definition, then, 1 of 12 (8.3%) non-diabetic controls was judged to be immunopositive for 
VP1 using this criterion (Figure 1). By contrast, multiple intensely vp-1 positive islet cells 
were observed in many insulin-containing islets (ICI) in 8 of the 17 nPOD type 1 diabetes 
cases. Of the remaining 9 cases, 7 were immunonegative for insulin. Hence, expression of 
VP1 was detected at well above the threshold level in the islet cells of 8 of the 10 nPOD 
cases (80%) in which ICI were present (Figure 1 and Table 1).  Representative VP1+ ICIs for 
both cohorts are shown in Figure 1A and B and the data are presented graphically in Figure 
1C.  
The absolute number of enteroviral VP1+ islet cells is elevated in organ donor cases by 
comparison with those recovered at autopsy. Quantification of the frequency of VP1+ ICIs 
in 7 VP1+ nPOD cases and 7 VP1+ UK cases was performed by counting the total number of 
islets containing one or more VP1+ cells within a given section. Analysis of both cohorts 
revealed that 65 of 227 (28.6%) islets from within the nPOD cases contained VP1+ cells; this 
compared with 77 of 374 (20.6%) islets within the UK cohort (Figure 2A, Table 1 and 
Supplementary Table 1). Therefore the frequency of VP1 immunopositive ICIs was similar 
between the two cohorts. However, when the absolute number of VP1+ cells within any 
given islets was studied and compared between the two cohorts, initial evidence implied that 
this number might be elevated in the nPOD cases (Figure 1). Therefore, in order to assess this 
more formally, a minimum of 20 randomly selected VP1+ islets were imaged from among 
the nPOD organ-donors (nPOD OD), UK organ-donors (UK OD) and UK post-mortem (UK 
PM) cases. The total number of endocrine cells contained within the imaged islets was 
recorded and correlated with the number of VP1+ endocrine cells. This revealed a significant 
increase in the number of individual VP1 positive endocrine cells present within any given 
islet among the organ donor samples (nPOD OD – 5.52±0.90%; UK OD – 5.10±0.87%; 
Figure 2B)  compared to the post-mortem cases (1.76±0.32%; p<0.001). Therefore the 
frequency of VP1+ islet cells seen in organ donors was similar in both cohorts (whether from 
the USA or the UK).   
Enteroviral VP1 co-localises with insulin in both the UK and the nPOD cohort. The 
observation that VP1+ islet cells were confined only to those nPOD cases in which  ICIs 
were also present, implies that VP1 might be preferentially localised within beta cells (as was 
reported previously for the UK cohort [7, 17]). In order to confirm this, 3 of the nPOD VP1+ 
cases were stained for the presence of both VP1 and insulin using dual immunofluorescence. 
A total of 31 VP1+ ICIs were identified. Overlaying the fluorescent images (Figure 3) 
revealed that VP1+ immunopositivity always co-localised with insulin. A similar situation 
pertained within the UK cohort. Interestingly, it was noted anecdotally, that the intensity of 
insulin staining appeared to be reduced in the VP1+ beta cells when compared to surrounding 
VP1- beta cells.  
Enteroviral VP1 co-localises with PKR in patients with type 1 diabetes. Enhanced 
expression of the pathogen recognition receptor PKR has been observed in VP1+ islets within 
the UK recent-onset type 1 diabetes patients [7] although it was not established whether VP1 
and PKR are preferentially localised within the same cells. To study the relative localisation 
of VP1 and PKR, dual immunofluorescence staining was performed in pancreas samples 
from both the UK and the nPOD cohorts. Within the 7 UK type 1 diabetes patients, 374 of 
866 islets (43.1%) contained cells that were immunopositive for insulin and VP1 was 
detected in 77 of these. Dual immunofluorescence staining confirmed that the VP1+ cells 
always co-expressed protein kinase R. A representative image of one such islet is presented 
in Figure 4. Similar co-localisation of VP1 and PKR within individual beta cells was also 
observed in the 31 VP1+ islets of the nPOD type 1 diabetes cases (Figure 4). PKR expression 
in surrounding cells tended to be slightly elevated with respect to background in the nPOD 
cases when compared to the UK cohort, where it was only the VP1+ cells which displayed 
clear immunoreactive PKR expression. 
Mcl-1 is present in beta cells but its expression is reduced in those cells containing VP1. 
PKR exists in both active (phosphorylated) and inactive (dephosphorylated) forms but it may 
be misleading to infer changes in specific protein phosphorylation patterns by immunological 
means in FFPE tissue due to potential changes arising during tissue fixation and processing. 
Therefore, we employed an alternative approach to assess the activity status of PKR in the 
islet cells of T1D patients. This was based on the understanding that the anti-apoptotic 
protein Mcl-1 is subject to rapid turnover in cells and that its levels decline quickly under 
conditions when protein translation is attenuated [18]. Since an important consequence of the 
activation of PKR is to inhibit protein translation in response to viral infection (via 
phosphorylation of eIF2α) we reasoned that Mcl-1 levels should decline in cells where PKR 
becomes activated. Therefore, the expression of Mcl-1 was evaluated in human FFPE 
pancreatic tissue and, more specifically we examined the intensity of immunostaining of Mcl-
1 in VP1+ cells (which, as shown above, always have elevated PKR) within the islets of the 
type 1 diabetes cases. Immunoperoxidase staining of non-diabetic control pancreas revealed 
intense staining of a subset of islet endocrine cells (Figure 5) confirming the presence of Mcl-
1 within certain islet cells. Dual immunofluorescence labelling revealed that these were beta 
cells (Figure 5). Importantly, the intensity of staining of Mcl-1 was markedly reduced (and 
was frequently undetectable) in those islet cells which were immunopositive for VP1.  
Example images are shown in Figure 6. To verify these data, 152 individual VP1+ islet cells 
were examined across a total of 8 different type 1 diabetes cases and scored for the presence 
of Mcl-1. Mcl-1 immunostaining was reduced (or was undetectable) in all cells expressing 
VP1, whereas Mcl-1 was stained much more intensely in adjacent, VP1-immunonegative, 
beta cells. 
DISCUSSION 
Previous studies have shown that, in patients with recent-onset type 1 diabetes, a proportion 
of islets contain cells in which the enteroviral capsid protein, VP1, can be detected by 
immunocytochemistry [5, 7]. This conclusion was first drawn by Dotta et al. based on studies 
of 5 patients with type 1 diabetes from Italy [5] and was substantiated by the analysis of a 
much larger cohort of samples collected from within the UK. These had been harvested from 
patients (mainly children) who died between 30-50 years ago and, among whom, the mean 
duration of diabetes was 8 months [7]. In the present work, it is shown that pancreas samples 
from a third group of patients with type 1 diabetes (who died within the USA and were 
collected since 2007) also contain islets that stain positively for enteroviral VP1. A group of 
relevant age-matched controls was employed to verify the selectivity of immunolabelling in 
each cohort and the results revealed that, while VP1 is occasionally detected in the islets of 
non-diabetic individuals, it is found much more abundantly in the cells of patients with type 1 
diabetes. As such, these data support the earlier conclusion that enteroviral infection of islet 
cells may be a characteristic feature of patients with type 1 diabetes in the Western world [7, 
19]. The current study also reveals that this feature is seen not only in patients with recent-
onset disease but also in a group with longer-standing type 1 diabetes, since the mean 
duration since diagnosis of diabetes in the nPOD samples analysed, was almost 12 years. 
This, in turn, reinforces the view that the nature of the infection occurring in the islet cells in 
type 1 diabetes is unusual in that it may persist over long periods rather than developing as an 
acute, lytic infection that is more typical of enteroviruses [19]. The results also show that 
both the historical UK collection and the nPOD samples represent suitable material for 
analysis of this infection in detail.  
The deduction that the enteroviral infection is persistent, may offer an explanation for our 
observation that the enteroviral capsid protein, VP1, is found in relatively few of the total 
number of islet cells available within each patient. As such, it has been proposed that 
detection of VP1 may be simply the “tip of an iceberg” in which many more cells harbour a 
latent infection and that, occasionally, this is manifest by the activation of viral protein 
synthesis within defined endocrine cells [19]. Mechanisms by which enteroviruses can persist 
in a latent form without causing large-scale cell lysis have been described [20-24] and we 
have confirmed that cultured mammalian cells which harbour such persistent infections in 
vitro are not routinely immunopositive for VP1 (SJ Richardson & NM Chapman; 
unpublished observations). However, the mechanism by which viral persistence is achieved 
in type 1 diabetes has not been defined and must await the final isolation and characterisation 
of the relevant viral serotype(s). 
A second important consideration arising from the present work is that immunodetection of 
VP1 should be undertaken only after rigorous optimisation of the staining pattern in pancreas 
samples. The most widely employed and robust antiserum available currently for 
immunodetection of VP1 in formalin fixed, paraffin embedded tissue samples is the 5D8/1 
monoclonal serum (Dako). However, we have noted that, in non-diabetic and diabetic 
pancreas samples from both the UK and nPOD cohorts, this serum can generate intense 
positivity in a wide range of endocrine and exocrine cells when employed at low dilution [7]. 
By contrast, when titrated to high dilution, the majority of this staining is lost and only 
occasional single, strongly immunopositive cells remain. In both cohorts these were 
exclusively beta cells, as judged by the pattern of co-staining with antisera to islet hormones. 
This is consistent with the earlier finding that beta cells express surface receptors capable of 
mediating enteroviral entry [25, 26].   
It is of interest that the dilution of clone 5D8/1 required for optimal immunostaining of nPOD 
samples was much higher (1:2000) than that which proved optimal for the UK cohort (1:500) 
and this may reflect the better tissue preservation of the former samples. In support of this, it 
was noted, too, that the mean number of VP1 immunopositive cells per islet (>5%) was 
greater in those samples recovered from organ donors (where tissue preservation was at a 
premium) compared with those collected at autopsy (<2%; where tissue preservation is less 
controlled). This finding held true both among the older UK cohort and within the more 
recent nPOD samples, such that the mean number of VP1 immunopositive cells per islet was 
similar in both organ donor groups (5.1 vs 5.5% respectively). This could be taken to imply 
that the frequency of enteroviral infection of beta cells has not changed dramatically over 
time or with geographical location between these two groups.  
A further critical issue is the identity of the immunoreactive protein labelled by the anti-VP1 
serum in the samples studied here. It is well-accepted that clone 5D8/1 binds to enteroviral 
VP1 encoded by a wide range of viral serotypes, but there remain hints in the literature that it 
may also bind to additional proteins (albeit with lower affinity) under certain conditions [9, 
27]. Indeed, as indicated above, we find that, at low dilution, the serum stains multiple cells 
(within and outside islets) in both control and type 1 diabetes patients [7] but that this issue is 
resolved at higher dilution. Nevertheless, it cannot be formally excluded that an additional 
(non-viral) target is labelled even under the more stringent conditions. However, if this is the 
case, then we now show that this response only occurs in cells which display certain critical 
additional features. In particular, we have studied samples from both the UK and nPOD 
cohorts and find that, remarkably (and without exception) beta cells which are 
immunopositive for VP1 also show intense immunostaining of the pathogen recognition 
receptor, PKR. This implies that the total amount of PKR protein is enhanced in these cells, 
presumably via induction of mRNA synthesis and translation. Previously, we had provided 
evidence (using serial sections examined by immunohistochemistry) that the same islets are 
stained positively by both antisera [7] but the present work now reveals that this staining is 
co-localised within the same individual beta cells. Hence, it can be concluded that these 
specific cells are mounting a response to an insult that is directly associated with VP1 
production. Since enteroviral infection has been shown to markedly up-regulate PKR 
expression in islet cells at the mRNA level [12, 13], the precise conjunction of the two 
phenomena monitored here, adds weight to the conclusion that VP1 expression is 
representative of underlying enteroviral infection. Having made this point, however, it must 
also be accepted that, in principle, the expression of PKR might also be induced by other 
(non-viral) stressors in beta cells. However, if this is the case, then it still remains true that the 
anti-VP1 serum must be capable of selectively labelling a unique subset of beta cells which 
are experiencing atypical stress.   
To advance these arguments further, we also investigated the status of Mcl-1 expression in 
islet cells in type 1 diabetes. Mcl-1 is an anti-apoptotic member of the Bcl-2 protein family, 
which due to unique motifs in its N-terminal domain, is subject to rapid turnover under 
normal conditions [18]. Therefore, in order to maintain adequate levels of Mcl-1 within the 
cell, the protein must be synthesised and replenished at a rate which is at least equal to its rate 
of degradation. Under conditions when PKR is activated, the translation initiation factor 
eIF2α becomes phosphorylated, leading to translational arrest and thereby to a reduction in 
the rate of Mcl-1 synthesis [14, 28]. As a result, Mcl-1 levels are expected to decline. This 
scenario has been confirmed recently in in vitro studies where it was shown directly that 
treatment of cultured beta cells with the viral dsRNA mimetic, poly-I:C (which will activate 
PKR) led to rapid loss of Mcl-1 from the cells [14].  
 In the present analysis, a similarly striking relationship was observed since, of 152 individual 
VP1 immunopositive beta cells studied in detail (across 8 different cases) all showed loss of 
immunoreactive Mcl-1 by comparison with those cells immediately adjacent to them. Since 
we have proven that VP1 expression is invariably correlated with PKR induction in beta cells 
in type 1 diabetes, these results also reveal that the PKR must have become activated under 
these conditions and that the cells had entered an anti-viral state in which bulk protein 
translation is arrested. As such, all of these features are fully consistent with the concept that 
viral infection underlies the response. If this is not the case and a specific subset of beta cells 
are responding to an unrelated stimulus (which, by chance, is identified uniquely, and with 
high affinity, by the anti-VP1 serum) then this stimulus must also be capable of causing the 
selective up-regulation and activation of PKR in only a small proportion of the available beta 
cells, thereby driving the loss of Mcl-1. Irrespective of the initiating mechanism, it should be 
emphasised that the loss of Mcl-1 is likely to render the cells more responsive to the cytotoxic 
actions of pro-inflammatory cytokines present within the islet milieu and that this could then 
play a role in their ultimate demise.  
On the basis of the data reported here, we suggest that the presence of immunoreactive VP1 
within beta-cells in human type 1 diabetes is associated with a cellular phenotype that could 
be indicative of viral infection and enhanced sensitivity to apoptosis. However, definitive 
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TABLE 1: nPOD Type 1 diabetes patients and non-diabetic controls 
Donor T1D/ Non-
diabetic 
Age Duration of 
T1D 
Block VP1 status  Insulin 
nPOD 6026 T1D 22.4 14 years PanBody-01 Negative No ICIs 
nPOD 6031 T1D 39 35 years PanBody-01 Negative No ICIs 
nPOD 6038 T1D 37.2 20 years PanBody-01 16 ICIs with multiple 
VP1+ cells 
 98 ICIs 
nPOD 6039 T1D 28.7 12 years PanBody-01 Negative No ICIs 
nPOD 6040 T1D 50 20 years PanTail-01 Negative No ICIs 
nPOD 6046 T1D 18.8 8 years PanBody-01 6 ICIs with multiple 
VP1+ cells 
14 ICIs 
nPOD 6051 T1D 20.3 13 years PanTail-01 4 ICIs with multiple 
VP1+ cells 
4 ICIs 
nPOD 6052 T1D 12 1 year PanTail-01 5 ICIs with multiple 
VP1+ cells 
10 ICIs 
nPOD 6063 T1D 4.4 3 years PanBody-01 Negative No ICIs 
nPOD  6069 T1D 23 7 years PanBody-01 Negative ICIs 
nPOD 6070  T1D 22.6 7 years PanBody-01 23 ICIs with multiple 
VP1+ cells 
61 ICIs 
nPOD 6081 T1D 31.4 15 years PanBody-02 Negative Multiple ICIs 
nPOD 6084 T1D 14.2 4 years PanBody-01 8 ICIs with multiple 
VP1+ cells 
34 ICIs 
nPOD 6088 T1D 31.2 5 years PanHead-03 3 ICIs with multiple 
VP1+ cells 
6 ICIs 
nPOD 6113 T1D 13.1 1 year PanBody-01 Negative No ICIs 





nPOD 6141 T1D 36.7 28 years PanBody-04 Negative No ICIs 
a
 The number of VP1+ islets and ICIs were not analysed in this case due to the unusual 
morphology of the tissue. 
TABLE 2: A comparison of the two cohorts from the UK and nPOD 
 UK Cohort nPOD Cohort 
Number of cases 72 17 
Mean Age 12.7±1.1y 25.7±2.9y 
Age Range 1-42y 4-50y 
Mean Time since diagnosis 8.2±4.1mths 11.9±2.3y 
Range Time since diagnosis 0-6y 1-35y 
Geography Scotland, England and Wales USA 
Sample Collection 1959-1983 2007 onwards 
Autopsy/ Organ Donors Autopsy and organ donors Organ Donors 






FIG. 1. Representative immunohistochemical images of enteroviral VP1 expression in the 
(a). UK (D4) and (b). nPOD cohorts (6052-01). (c). The proportion of islets staining intensely 
positive for VP1. White bars – non diabetic controls; hatched bars – type 1 diabetes cases 
with insulin-containing islets (ICIs); black bars – type 1 diabetes cases containing only 
insulin-deficient islets (IDIs). 
FIG. 2. a: Detailed analysis of the proportion of ICIs with VP1+ cells in 166 ICIs from the 
nPOD cohort (black bars) and from 374 ICIs from the UK cohort (white bars). b: Analysis of 
the percentage of total endocrine cells that are VP1+ in UK post-mortem (PM) cases (white 
bars; n=21 islets), UK organ donor (OD) cases (black bars; n=20 islets) and nPOD OD 
(hatched bars; n=25 islets). 
FIG. 3. Photomicrographs of representative islets from the nPOD (upper panel; 6052-01) and 
UK (lower panel; D4) cohorts reveals that VP1 (red; c, d) co-localises with insulin (green; a, 
b). Double positive cells are stained yellow and are visible in e and f. Nuclear DAPI staining 
is shown in blue in the merged images (e and f).  
FIG. 4. Photomicrographs of representative islets from the nPOD (upper panel; 6084-01) and 
UK (lower panel; D4) cohorts reveals that VP1 (green; a, b) co-localises with PKR (red; c, d). 
Double positive cells are stained yellow and are visible in e and f. Nuclear DAPI staining is 
shown in blue in the merged images (e and f). 
FIG. 5. A. Light microscopic image of Mcl-1 expression in the islet of a non-diabetic control 
demonstrates intense staining of a subset of islet endocrine cells. b-d. Fluorescence 
microscopic analysis of a representative islet from a UK case reveals that Mcl-1 (red; c) co-
localises with insulin (green; b). Double positive cells are stained yellow and are visible in d. 
Nuclear DAPI staining is shown in blue in the merged images (d). 
FIG. 6. Photomicrographs of a representative islet from a UK case reveals that the VP1+ 
cells (green staining outlined in yellow); a) have reduced Mcl-1 expression (red; b) when 
compared to surrounding beta cells that are shown to express high levels of Mcl-1 (purple in 
merged image (c). Autofluorescent red blood cells are indicated with asterisks (*). 
 
 
 
 
